Gentian Diagnostics AS in brief
Gentian Diagnostics AS is a listed company in the Diagnostics and Research industry, based in Norway. Its last known market value was $71 M (July 2023); there is no current figure. In the year to December 2025 it had sales of $17 M and a net profit of $1 M, about 8 cents of profit for every dollar of sales. Its shares trade under the symbol 6FK.F (Frankfurt).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
Gentian Diagnostics AS timeline
- 2001
- 🏁· approximateIncorporated as Gentian Diagnostics Asa
- 2016
- •Legal Entity Identifier issuedLEI 5967007LIEEXZXHNM861 registered.
Events of Gentian Diagnostics AS from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Norway: #175 (Jan 2022) · #161 (Dec 2022) · #162 (Jul 2023)
Key ratios
- P/E ratio
- —
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- 7.5%
- Operating margin
- 14.4%
- Return on equity
- 6.3%
- Liabilities / assets
- 20.7%
- Revenue growth
- +20.0%
- R&D / revenue
- 13.1%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $17M | +20.0% | $2M | $1M | 7.5% |
| Dec 2024 | $14M | — | $1M | $4M | 29.8% |
| Dec 2023 | — | — | — | $4M | — |
| Dec 2022 | — | — | — | $5M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $4M | $0M | $4M | $8.28 | — |
| Dec 2024 | $1M | $0M | $1M | $26.71 | — |
| Dec 2023 | — | — | — | — | — |
| Dec 2022 | — | — | — | — | — |
Annual results
- Revenue
- $17 M
- Operating income
- $2 M
- Net income
- $1 M
For year ending December-2025 · source: official annual report (ESEF)
Balance sheet
- Total assets
- $26 M
- Total liabilities
- $5 M
- Total equity
- $20 M
As of December-2025
Gentian Diagnostics AS scorecard#
Passes 3 of the 5 checks that could be worked out. Fiscal year 2025.
Valuationnot known
Growth1 of 2
Profitability2 of 3
Financial healthnot known
Shareholder returnsnot known
Worked out from the statements as filed (esef), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Gentian Diagnostics AS's statements, beside the median of Diagnostics and Research.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 14.4% | -2.4% | |
| Net margin | 7.5% | -3.6% | |
| Return on equity | 6.8% | -5.4% | |
| Revenue growth | 20.0% | 6.6% | |
| Free cash flow margin | 23.4% | 4.7% |
4of 6on the Piotroski tests of financial strength
Gentian Diagnostics AS: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in NOK millions; per-share figures in NOK; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 176 | 152 | 135 | 102 | 83 | 63 | |
| Gross profit | 98 | 83 | — | — | — | — | |
| Research and development | 23 | 22 | — | — | — | — | |
| Selling and marketing | 29 | 28 | — | — | — | — | |
| Total costs and expenses | — | — | 155 | 135 | 123 | 97 | |
| Operating income | 25 | 16 | −13 | −23 | −23 | −18 | |
| Interest and finance income | 5.4 | 6.9 | 5.8 | 3.8 | 2.1 | 1.8 | |
| Interest expense and finance costs | 5.2 | 2.5 | 3.4 | 4.2 | 4.0 | 1.5 | |
| Income before tax | 26 | 20 | −10 | −24 | −25 | −17 | |
| Income tax | 12 | −25 | 0.3 | 0 | 0 | 0 | |
| Net income including minority interests | 13 | 45 | −11 | −24 | −25 | −17 | |
| Earnings per share, basic | 86.00 | 294.00 | -0.69 | -1.53 | — | — | |
| Earnings per share, diluted | 86.00 | 287.00 | -0.69 | -1.53 | -1.61 | -1.13 | |
| Balance sheet | |||||||
| Cash and cash equivalents | 106 | 85 | 88 | 82 | 115 | 158 | |
| Receivables | 24 | 31 | 17 | 19 | 23 | 15 | |
| Current assets | 184 | 162 | 142 | 139 | 167 | 194 | |
| Property, plant and equipment | 4.4 | 6.3 | 7.8 | 9.3 | 3.4 | 3.9 | |
| Right-of-use (leased) assets | 21 | 7.8 | — | — | — | — | |
| Other intangible assets | 36 | 28 | 21 | 27 | 25 | 16 | |
| Non-current assets | 74 | 68 | 39 | 48 | 44 | 41 | |
| Total assets | 259 | 230 | 181 | 188 | 212 | 235 | |
| Current liabilities | 34 | 30 | 25 | 22 | 23 | 23 | |
| Lease liabilities (non-current) | 19 | 5.5 | 9.0 | 12 | — | — | |
| Non-current liabilities | 19 | 5.5 | 9.1 | 12 | 14 | 18 | |
| Total liabilities | 54 | 36 | 34 | 34 | 37 | 41 | |
| Retained earnings | −115 | −122 | −167 | −156 | −133 | −108 | |
| Total equity | 205 | 194 | 147 | 154 | 175 | 195 | |
| Total liabilities and equity | 259 | 230 | 181 | 188 | 212 | 235 | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 9.1 | 9.0 | 9.6 | 10 | 7.4 | 6.6 | |
| Share-based compensation | 3.3 | 2.6 | 3.0 | 3.4 | 4.6 | 3.3 | |
| Cash from operating activities | 43 | 13 | 15 | −14 | −27 | −13 | |
| Capital expenditure | −1.2 | −1.4 | −1.0 | −8.6 | −1.0 | −2.7 | |
| Intangible assets bought | −9.6 | −9.6 | −3.5 | −6.0 | −12 | −3.7 | |
| Acquisitions, net of cash acquired | — | — | −0.4 | 0 | — | — | |
| Cash from investing activities | −11 | −11 | −4.9 | −15 | −13 | 0.3 | |
| Debt issued | — | — | — | — | 0 | 0.5 | |
| Debt repaid | — | — | — | — | −3.7 | −2.5 | |
| Shares issued | — | — | — | — | 0.6 | 0.5 | |
| Dividends paid | −6.2 | 0 | — | — | — | — | |
| Cash from financing activities | −11 | −5.0 | −4.6 | −4.3 | −3.1 | −1.5 | |
| Exchange-rate effect on cash | 0.5 | −0.5 | 0.1 | −0.4 | −0.1 | 0.2 | |
| Report | ESEF | ESEF | ESEF | ESEF | ESEF | ESEF | |
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Dec 31, 2025
How Gentian Diagnostics AS compares in Diagnostics and Research
- Revenue$17 M · higher than 17% of 123
- Net margin7.5% · higher than 59% of 112
- Revenue growth20.0% · higher than 80% of 90
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Gentian Diagnostics AS🇳🇴 | $71 M | — | 7.5% | +20.0% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Thermo Fisher Scientific Inc.$253.8 B
- Danaher Corporation$166.7 B
- WuXi AppTec Co., Ltd.$70.4 B
- Natera, Inc.$58.7 B
- Siemens Healthineers AG$52.8 B
- Lonza Group AG$51.9 B
How current the figures are
- Market cap:
- Jul 30, 2023 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 15, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Gentian Diagnostics AS? Verify and update this profile — free
Show Gentian Diagnostics AS's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.